We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Celtic Pharma and PolyTherics Announce Investment into Biopharmaceutical Programme
News

Celtic Pharma and PolyTherics Announce Investment into Biopharmaceutical Programme

Celtic Pharma and PolyTherics Announce Investment into Biopharmaceutical Programme
News

Celtic Pharma and PolyTherics Announce Investment into Biopharmaceutical Programme

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Celtic Pharma and PolyTherics Announce Investment into Biopharmaceutical Programme"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Celtic Pharma Holdings Advisors LLP (CPHA), the advisor to Celtic Pharma Holdings II LP (CP2), together with PolyTherics Limited (PolyTherics), announces an investment by Leverton Licence Holdings Limited (LLH), a wholly-owned subsidiary of CP2, into a research programme to develop a novel biopharmaceutical molecule.

This research programme will be undertaken jointly by PolyTherics and Cantab BioPharmaceuticals Limited (Cantab), a wholly-owned subsidiary of CP2 based in Cambridge, UK.

PolyTherics will receive an upfront payment and ongoing technical support for the research, while LLH may elect to submit two further proteins for research under the collaboration.

PolyTherics grants LLH an option to license products arising from the research collaboration, with PolyTherics receiving a share of any commercial returns. Further details of the agreement terms were not disclosed.

Dr Keith Powell, Chief Executive Officer of PolyTherics, said: “We are delighted to establish a working relationship with CP2 and its subsidiaries Cantab and LLH through this new therapeutic programme. Importantly, as we embark as a company on the development of our own bio-better products, we are excited to share in the rewards of product commercialization resulting from this new collaboration”.
Advertisement